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Abstract
Background: Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in
multiple intracellular signaling pathways promoting tumor growth. mTOR is aberrantly activated in
a significant portion of breast cancers and is a promising target for treatment. Rapamycin and its
analogues are in clinical trials for breast cancer treatment. Patterns of gene expression (metagenes)
may also be used to simulate a biologic process or effects of a drug treatment. In this study, we
tested the hypothesis that the gene-expression signature regulated by rapamycin could predict
disease outcome for patients with breast cancer.
Results: Colony formation and sulforhodamine B (IC50 < 1 nM) assays, and xenograft animals
showed that MDA-MB-468 cells were sensitive to treatment with rapamycin. The comparison of
in vitro and in vivo gene expression data identified a signature, termed rapamycin metagene index
(RMI), of 31 genes upregulated by rapamycin treatment in vitro as well as in vivo (false discovery rate
of 10%). In the Miller dataset, RMI did not correlate with tumor size or lymph node status. High
(>75th percentile) RMI was significantly associated with longer survival (P = 0.015). On multivariate
analysis, RMI (P = 0.029), tumor size (P = 0.015) and lymph node status (P = 0.001) were prognostic.
In van 't Veer study, RMI was not associated with the time to develop distant metastasis (P = 0.41).
In the Wang dataset, RMI predicted time to disease relapse (P = 0.009).
Conclusion: Rapamycin-regulated gene expression signature predicts clinical outcome in breast
cancer. This supports the central role of mTOR signaling in breast cancer biology and provides
further impetus to pursue mTOR-targeted therapies for breast cancer treatment.
Background
Mammalian target of rapamycin (mTOR) is a serine/thre-
onine kinase involved in multiple intracellular signaling
pathways promoting tumor growth [1]. The phosphati-
dylinositol 3-kinase (PI3K)/Akt/mTOR signaling pathway
in particular is deregulated in many cancers, including
breast cancer. PI3K activates Akt, which regulates various
cellular processes and promotes cell survival. mTOR is a
downstream effector of the PI3K/Akt pathway and phos-
phorylates S6 kinase (S6K1) and 4E-binding protein-1
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(4E-BP1), which control cell growth and proliferation and
protein translation. Furthermore, PI3K is a mediator of
oncogenesis in breast cancer cases. Mutations in the PI3K
catalytic subunit p110α [2,3] and overexpression of
growth factor receptors such as HER2/neu [4], epidermal
growth factor receptor [5], insulin-like growth factor
receptor [6], and integrins [7] may activate PI3K signaling.
Additionally, phosphatase and tensin homologue deleted
from chromosome 10 (PTEN) is a negative regulator of
the PI3K/Akt pathway. Germ-line PTEN mutations lead to
Cowden disease, which predisposes patients to breast can-
cer. PTEN is downregulated in one third of patients with
breast cancer [8] and PTEN loss is associated with poor
prognosis for this malignancy [9]. In addition, authors
have reported Akt1 mutations [10], increased Akt1 kinase
activity [11], genomic amplification of Akt2 [12], and
overexpression of phosphorylated Akt protein [13]. Thus,
various aberrations activate mTOR, which has a key role
in translation, cell growth, apoptosis and angiogenesis.
Rapamycin is an antibiotic and fungicide isolated from
Streptomyces hygroscopicus [14]. It forms a complex with
FK506-binding protein 12 that binds and inhibits mam-
malian target of TOR kinase activity, leading to dephos-
phorylation of downstream targets of mTOR, S6K1, and
4E-BP1 [15]. S6K1 and 4E-BP1 regulate ribosomal com-
ponent biogenesis and cap-dependent mRNA translation,
and their dephosphorylation inhibits translation of
mRNAs involved in cell cycle, proliferation, and induc-
tion of growth arrest at G1 phase.
The U.S. Food and Drug Administration approved
rapamycin analog temsirolimus (Toricel, CCI-779;
Wyeth) and everolimus (Afinitor, RAD001, Novartis) for
patients with advanced renal cell carcinoma. Clinical trials
evaluating the efficacy of rapamycin and its analogs alone
or in combination with other agents in patients with
breast cancer are ongoing. However, in the Phase II trial of
temsirolimus in heavily pretreated locally advanced or
metastatic breast cancer, temsirolimus produced an objec-
tive response rate of 9.2% in the intent-to-treat popula-
tion [16]. Thus there is an urgent need to identify minority
subpopulations of patients that are sensitive to certain
pathway inhibition, better understand the mechanism of
action of rapamycin and its analogs, and identify markers
of pathway activity.
Researchers are actively pursuing transcriptional profiling
as a prognostic and predictive tool in breast cancer ther-
apy. Transcriptional response to modulation of a gene or
signaling pathway may not only allow identification of
novel targets of well-characterized genes but may also
define a pattern of mRNA expression (metagene), which
can serve as a molecular indicator of gene and/or pathway
activation [17]. Recent studies identified gene expression
signatures of several pathways, such as Akt [18], cyclin D1
[19], KRAS2 [20], Myc, Ras, E2F3, Src, β-catenin [21],
ErbB2, epidermal growth factor receptor, Raf, and MEK
[22]. In the study described herein, we defined a rapamy-
cin-regulated gene signature as a set of genes whose
expression is upregulated when mTOR activity is inhib-
ited by rapamycin in vitro as well as in vivo. We hypothe-
sized that this rapamycin-regulated gene signature
determines prognosis for breast cancer, and we tested its
ability to predict the outcome of this disease using three
independent publicly available primary breast cancer data
sets.
Results
Identification of differentially expressed genes in breast 
cancer cells and generation of a rapamycin-regulated gene 
expression signature
We sought to identify genes differentially expressed in
response to treatment with rapamycin in MDA-MB-468
cells, a PTEN-null human breast cancer cell line with con-
stitutive activation of PI3K/Akt/mTOR signaling [23-25].
To confirm the rapamycin sensitivity of MDA-MB-468
cells in vitro, we treated them with rapamycin at concen-
trations ranging from 0.1 to 1000 nM for 5 days. Fig. 1A
shows the inhibitory effect of rapamycin on cell growth.
The IC50  of rapamycin was less than 1 nM. We also
assessed the effect of rapamycin on anchorage-dependent
growth of MDA-MB-468 cells using a colony formation
assay. Rapamycin treatment resulted in a significant
decline in colony-forming ability in these cells (P  =
0.0023) (Fig. 1B).
To determine rapamycin's effects on in vivo tumor growth,
we injected MDA-MB-468 cells into mammary fat pads of
athymic nude mice. We then gave the animals injections
of DMSO or rapamycin (15 mg/kg weekly) intraperito-
neally for 3 weeks. We observed a statistically significantly
lower mean tumor volume (P < 0.05) on day 22 after
injection in the mice given rapamycin (140 mm3) than in
the control mice (355 mm3) (Fig. 1C). This demonstrated
that MDA-MB-468 cells are sensitive to the growth-inhib-
itory effect of rapamycin in vivo.
The ratio of total expression of rapamycin-treated RNA to
that DMSO-treated RNA defined the changes in the tran-
scriptional states for individual RNAs. Of the 1271 differ-
entially expressed genes by rapamycin treatment, 477
showed upregulation and 794 showed downregulation in
vitro (false discovery rate [FDR] = 10%). To examine early
and late rapamycin-mediated gene-expression changes in
vivo, we assessed the effect of rapamycin on MDA-MB-468
xenografts in nude mice after 24 h and 3 weeks of treat-
ment. These specific time-points were selected as 24 h and
3 week post-treatment biopsies have been incorporated
into some of the ongoing clinical trials with rapamycinMolecular Cancer 2009, 8:75 http://www.molecular-cancer.com/content/8/1/75
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and its analogues. There was no significant interaction
between treatment (vehicle and rapamycin) and time (1-
day and 22-day) in vivo study. However, treatment and
time regulated expression of several genes. Gene set
enrichment analysis (GSEA) results show upregulated and
downregulated gene sets (See Additional files 1, 2, 3: Gene
set enrichment analysis of in vivo data) [26]. Treatment
effect is regulating genes sets that are involved in immune
response and metabolism, whereas time effect regulates
gene sets that are involved in hypoxia, cancer and metab-
olism.
We used the averages of rapamycin and vehicle treatment
over two time points, of the 377 differentially expressed
genes, 303 showed upregulation and 74 showed down-
regulation in vivo (FDR = 10%). To identify genes whose
expression was regulated in vitro and in vivo, we com-
pared differentially expressed genes using Affymetrix
probe set identifiers which generated a list of 34 entries.
Treatment with rapamycin upregulated the expression of
31 of these probes and downregulated that of 3. We then
used these 31 probe sequences belonging to 29 genes
whose expression was upregulated by rapamycin and des-
ignated this gene signature as the rapamycin metagene
index (RMI) (Table 1). One of these probe sequences did
not have a matching gene sequence, and granulin had two
hits; expression of both probe sets was upregulated. The
three downregulated genes that were not included in the
RMI were DDIT4, GPR107 and ZNF419.
The RMI as a prognostic factor for breast cancer in the 
independent primary breast cancer data sets
We hypothesized that if rapamycin indeed regulates a crit-
ical oncogenic pathway in breast cancer, then RMI would
correlate with breast cancer outcome. To determine
whether the RMI can provide prognostic information
about breast cancer, we applied it to the three well-
described, publicly available primary breast cancer data
Rapamycin sensitivity of the MDA-MB-468 breast cancer cell line Figure 1
Rapamycin sensitivity of the MDA-MB-468 breast cancer cell line. (A) MDA-MB-468 cells were treated with rapamy-
cin at various concentrations. SRB assay was performed 5 days later. The assay results shown are the mean (± standard devia-
tion) of three independent experiments. (B) 2 × 103 MDA-MB-468 cells were plated in 60-mm plates in triplicate and treated 
with DMSO or 100 nM rapamycin. Two weeks later, cell colonies were stained with crystal violet, and the plates were scanned 
and colonies quantitated. The results shown are the mean (± standard deviation) for three plates. (C) Mice with established 
MDA-MB-468 tumor xenografts received DMSO or rapamycin (15 mg/kg) intraperitoneally once a week for 3 weeks. The 
tumor volumes were then measured using calipers every other day and presented as the mean (± standard error of the mean). 
Solid line, rapamycin; dashed line, DMSO. * P < 0.05.
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Table 1: The 31 probe sets (29 genes) in Rapamycin Metagene Index listed by probe set identifier.
Probe set ID Gene symbol Gene title Included in HG-U133 array
202050_s_at ZMYM4 Zinc finger, MYM-type 4 Yes
202623_at C14orf1 E2F-associated phosphoprotein Yes
203985_at ZNF212 Zinc finger protein 212 Yes
204279_at PSMB9 Proteasome 
(prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2)
Yes
204985_s_at MGC2650 Trafficking protein particle complex 6A Yes
208669_s_at CRI1 CREBBP/EP300 Yes
209101_at CTGF Connective tissue growth factor Yes
209102_s_at HBP1 HMG-box transcription factor 1 Yes
209216_at WDR45 WD repeat domain 45 Yes
210296_s_at PXMP3 Peroxisomal membrane protein 3, 35 kDa (Zellweger syndrome) Yes
211284_s_at GRN Granulin Yes
214177_s_at PBXIP1 Pre-B-cell leukemia transcription factor-interacting protein 1 Yes
215464_s_at TAX1IP3 Tax1 (human T-cell leukemia virus type I)-binding protein 3 Yes
216041_x_at GRN Granulin Yes
217906_at KLHDC2 Kelch domain containing 2 Yes
218550_s_at LRRC20 Leucine-rich repeat containing 20 Yes
219630_at MAP17 PDZK1-interacting protein 1 Yes
221087_s_at APOL3 Apolipoprotein L, 3 Yes
221476_s_at RPL15 Ribosomal protein L15 Yes
46256_at SSB3 SPRY domain-containing SOCS box protein SSB-3 Yes
1555852_at - - No
222574_s_at DHX40 DEAH (Asp-Glu-Ala-His) box polypeptide 40 No
222802_at EDN1 Endothelin 1 No
223042_s_at FUNDC2 FUN14 domain-containing 2 No
223493_at FBXO4 F-box protein 4 No
224564_s_at RTN3 Reticulon 3 No
224785_at MGC29814 Hypothetical protein MGC29814 NoMolecular Cancer 2009, 8:75 http://www.molecular-cancer.com/content/8/1/75
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sets described above. The sets described by Miller et al.
[27] and by Wang et al. [28] were Affymetrix-based data
sets, and we correlated the gene-expression levels with our
study using the corresponding probe set identifiers. We
analyzed the HG-U133A probe set in the data set
described by Miller and colleagues. Of the 31 probes in
the HG-U133 Plus 2.0 chips, we included 20 that were
present in HG-U133A array and used them for cross-study
comparisons. We also applied RMI to van 't Veer data set
which was performed by using Hu25K microarray chip
(Agilent platform) [29]. The probes in our and Wang data
sets were matched by using gene symbols and 26 of the 29
genes were present. The data set used by Miller et al. rep-
resents 251 patients with primary breast cancer who
underwent surgery. They used no patient selection criteria.
In this data set, the RMI did not correlate with the follow-
ing known prognostic factors for breast cancer: tumor size
(P = 0.36), lymph node status (P = 0.93), and patient age
(P  = 0.22) (Fig. 2). However, the overall survival rate
based on the high and low RMI values showed a signifi-
cant difference in between the two values (P = 0.015),
with the high RMI group having longer survival rates (Fig.
3). Multivariate analysis indicated that RMI (P = 0.029),
tumor size (P = 0.015), and lymph node status (P = 0.001)
were prognostic for overall survival in breast cancer (Table
2). van 't Veer et al. [29] selected 97 patients with sporadic
primary breast cancer who had lymph node-negative dis-
ease and were younger than 55 years of age at the time of
diagnosis. RMI was not associated with time to develop-
ment of distant metastasis in these patients (P = 0.41).
Wang et al. [28] included in their data set 286 patients
with lymph node-negative breast cancer who did not
receive systemic neoadjuvant or adjuvant therapy. In this
data set, the RMI predicted the metastasis-free survival rate
(P = 0.009), with the high RMI value associated with a bet-
ter disease course than the low RMI value was (Fig. 4).
Discussion
The mTOR pathway is activated in breast cancer and has
become a promising target for breast cancer therapy.
mTOR activation contributes to the malignant phenotype
by increasing protein synthesis, cell proliferation, angio-
genesis, and nutrient uptake. Herein we show that the
RMI is associated with overall and metastasis-free survival
rate in patients with breast cancer. Furthermore, our mul-
tivariate analysis showed that the RMI is prognostic for
225076_s_at KIAA1404 Zinc finger, NFX1-type containing 1 No
225898_at WDR54 WD repeat domain 54 No
226157_at TFDP2 Transcription factor Dp-2 (EF2 dimerization partner 2) No
227475_at FOXQ1 Forkhead box Q1 No
ID, identifier.
Table 1: The 31 probe sets (29 genes) in Rapamycin Metagene Index listed by probe set identifier. (Continued)
Table 2: Cox multivariate regression analysis of survival according to clinical factors in the primary breast cancer data sets used.
Miller et al. [27] Wang et al. [28] van 't Veer et al. [29]
Factor HR 95% CI P HR 95% CI P HR 95% CI P
RMI 0.03a 0.00-0.69 0.029 0.27 0.10-0.71 0.008 0.23 NS 0.28
LN status (negative versus positive) 2.74 1.50-5.01 0.001
Tumor sizeb 1.03 1.01-1.06 0.015
Ageb 1.01 0.99-1.03 NS
Grade (low [1 or 2] versus high 3) 1.43 0.90-2.26 NS
ER status (negative versus positive) 1.44 0.60-3.48 NS 1.07 0.69-1.65 NS 0.57 0.32-1.03 NS
Clinical data and the RMI with relative risk (hazards ratio), confidence interval, and P value were fitted to each of the clinical factors.
aA coefficient of 0.03 means that the model gives a 97% decrease of the predicted hazard for an increase of 1 unit of RMI.
bThere was no stratification of the variables, actual values were used in analysis.
HR, hazards ratio; CI, confidence interval; LN, lymph node; NS, not significant; ER, estrogen receptor.Molecular Cancer 2009, 8:75 http://www.molecular-cancer.com/content/8/1/75
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breast cancer. These data indicate that the mTOR pathway
is important to breast carcinogenesis.
By identifying human microarray probe sets correspond-
ing to the genes in the three data sets impacted by rapamy-
cin treatment, we identified a rapamycin-regulated gene
expression signature that predicts prognosis for breast
cancer. Several studies have characterized transcriptional
response to treatment using cell culture experiments,
whereas others have related in vitro experiments with in
vivo experimental models [20,30]. Gene expression signa-
tures generated in cell lines may be predictive of clinical
response, suggesting that despite major differences in
tumor microenvironment, at least some key oncogenic
signatures are conserved in vitro and in vivo. Thus, we may
be able to effectively use preclinical data to discover clini-
cally relevant biomarkers. Our strategy described above of
combining preclinical data obtained in cell culture exper-
iments as well using established xenograft models may
generate a robust gene expression signature that may be
useful for both in vitro and in vivo studies. We also applied
GSEA and determined the effect of treatment and time in
vivo. Compared to 1-day treatment, 22-day treatment
(time effect) increased the expression of gene sets
involved in response to hypoxia and cancer. These find-
Lack of correlation of the RMI with prognostic factors for breast cancer in Miller et al. data set [27] Figure 2
Lack of correlation of the RMI with prognostic factors for breast cancer in Miller et al. data set [27]. The nonpar-
ametric box plots show interquartile range, horizontal line is mean. The RMI is distributed according to (A) tumor size, (B) 
lymph node status, and (C) patient age. o, outlier.
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Overall survival rate according to the RMI in patients with  breast cancer in Miller et al. data set [27] Figure 3
Overall survival rate according to the RMI in patients 
with breast cancer in Miller et al. data set [27]. Overall 
survival rate based on high and low RMI values were calcu-
lated using Cox proportional hazards analysis.
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Metastasis-free survival rate according to the RMI in patients  with breast cancer in Wang et al. data set [28] Figure 4
Metastasis-free survival rate according to the RMI in 
patients with breast cancer in Wang et al. data set 
[28]. Metastasis-free survival rate based on high and low RMI 
values were calculated using of Cox proportional hazards 
analysis.
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ings further support importance of mTOR as a central con-
troller integrating signals coming from separate pathways.
Other researchers have also investigated the effect of treat-
ment with rapamycin and its analogues on gene expres-
sion. Gera et al. [31] studied Akt activation and mTOR
inhibition by rapamycin in prostate cancer and glioblast-
oma cell lines in vitro. They identified 62 regulated genes
and expression of 29 them were upregulated; however,
none of these genes were on our RMI list. Majumder et al.
[32] used a transgene to produce activated Akt1 in lumi-
nal epithelial cells in the ventral murine prostate. A pros-
tatic intraepithelial neoplasia (PIN) phenotype developed
in the transgenic mice, which was completely reversed by
mTOR inhibition by the rapamycin analogue everolimus
(RAD001; Novartis), by inducing apoptosis. They identi-
fied 571 genes or ESTs whose expression was altered by
Akt expression and mTOR inhibition. Further analysis by
using gene set enrichment analysis (GSEA) revealed inac-
tivation of hypoxia inducible factor 1α (HIF-1α) and its
target genes, including genes coding enzymes involved in
glycolysis pathway, which are all regulated by mTOR. We
used our rapamycin-responsive gene set to probe the gene
set used in that study and identified only endothelin 1
gene common in both sets. Interestingly, in our study
endothelin 1 gene expression was downregulated whereas
in Majumder et al. study upregulated. Besides, rapamycin
treatment does not induce apoptosis in breast cancer cell
lines [25], thus the downstream effects of rapamycin in
these two models may be different. Absence of concord-
ance may not be surprising considering this is a compari-
son of gene expression in a breast cancer cell line with that
of a model of Akt-activated mouse PIN. As stated by
Majumder et al., cell lines and xenografts show a more
complex genetic background than an Akt-activation
model as survival and adaptive events have already taken
place. Creighton re-analyzed the Majumder et al. study
data and identified "Akt-mTOR-dependent (RAD001-sen-
sitive)" genes, which were higher in human breast tumors
having high Akt mRNA [18]. This signature of 101 genes
was applied to five publicly available breast cancer data-
bases and high expression of these genes in several data-
sets were associated with more metastasis, shorter time of
disease free survival, ER negative status, higher grade, and
increase in tumor size. This was an application of Akt-
mTOR signature derived from a mouse model of Akt acti-
vation in prostate to human breast cancer showing that
the genes were not tissue or model specific. There were no
matches between RMI and Akt-mTOR-dependent gene
signatures. Also of note, Saal et al. generated an "immuno-
histochemistry-detectable PTEN loss" signature in breast
cancer showing activation of PI3K/Akt signaling pathway
[33]. This signature of 246 genes was applied to two estab-
lished breast cancer datasets and identified metastasis and
poor prognosis [33]. There were no matches between RMI
and PTEN loss gene signatures. Thus, although we and
Creighton, and Saal et al. used different gene expression
signatures, all mTOR-regulated gene sets were prognostic
for breast cancer, supporting an important role for mTOR
in breast cancer. This agrees with the results of studies of
the prognostic role of mTOR pathway activation in breast
cancer using immunohistochemistry. In a tissue array-
based analysis of 285 patients with breast cancer, Bose et
al. [13] showed that overexpression of phosphorylated
mTOR increased the risk of recurrence threefold. Simi-
larly, using immunohistochemistry, Zhou et al. [34]
showed that overexpression of phosphorylated mTOR
protein in breast cancer is an indicator of decreased dis-
ease-free survival rate, whereas decreased expression of
phosphorylated Akt and phosphorylated 4E-BP1, which is
an mTOR downstream target, are indicators of increased
disease-free survival rate.
Use of microarrays enables simultaneous analysis of thou-
sands of genes in a single step, which leads to identifica-
tion of groups of genes working in a similar way. Because
several genes are involved in the same biological proc-
esses, the fact that several gene sets carry prognostic infor-
mation for cancer and that gene signatures generated in
different studies may not overlap is not surprising. Tech-
nical differences among the studies contribute to the dis-
crepancy in gene expression data, such as different
microarray platforms, probes, RNA-labeling methods,
and gene sets [35]. Microarray-based studies of breast can-
cer usually focus on three main uses of gene expression
profiling [36]. First, gene expression profiling may can
generate a molecular classification of breast cancer into
different subsets according to clinical subtype, such as
high versus low grade [37-41]. Second, profiling of genes
associated with clinical outcome of patients, such as time
to death or relapse, may help clinicians predict risk of fail-
ure after surgery [28,29,42,43] and individualize the use
of adjuvant therapy based on the predicted risk of relapse.
Third, gene expression profiling may be used to predict
breast cancer response to specific treatment regimens,
which is potentially best studied in the neoadjuvant set-
ting [21,44-46]. A predictive gene signature may be used
to identify patients, whose disease will not respond to one
drug regimen but will to another regimen, thereby making
breast cancer treatment more precise and individualized.
In this study, we applied RMI to independent primary
breast cancer data sets to confirm the importance of
mTOR signaling in breast cancer biology. We identified a
rapamycin-regulated gene signature that is a significant
predictor of breast cancer prognosis. For clinical use, iden-
tifying rapamycin-mediated gene expression changes in a
variety of tumors responsive to mTOR inhibition would
be ideal. Although several clinical trials using correlative
studies are ongoing, the results have been slow to arrive.Molecular Cancer 2009, 8:75 http://www.molecular-cancer.com/content/8/1/75
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The reason for this is that many of these trials are con-
ducted in the metastatic setting, in which accessibility and
the relative tumor cellularity of metastatic tumors are lim-
iting, as is the relatively modest objective response rates
achieved using single-agent therapy. Thus, identification
of oncogenic gene expression signatures in the preclinical
setting using well-characterized rapamycin-sensitive can-
cer models may facilitate discovery of profiles that can
then be tested prospectively in the clinic and retrospec-
tively.
Although researchers are actively studying mTOR inhibi-
tors in the treatment of many tumor types in hundreds of
clinical trials, which patients will have a response and/or
clinically benefit from mTOR inhibition remains unclear.
Thus, the need to identify markers of response to mTOR
inhibitors for patient selection and pharmacodynamic
markers for early response assessment is a pressing one.
Further work is needed to determine whether examina-
tion of the RMI can identify patients with breast cancer
who have baseline activation of mTOR signaling and thus
would benefit from treatment with rapamycin or its ana-
logues. It also needs to be determined whether an increase
in the RMI in response to treatment to rapamycin may
serve as an early indicator of clinical response to mTOR
inhibition. Because rapamycin modulates gene expression
postranscriptionally [31,47,48], we are also seeking to
determine whether incorporation of functional proteom-
ics complements gene expression profiling in identifica-
tion of patients with breast cancer who have activation of
mTOR signaling and monitoring response of breast cancer
to therapy.
Methods
Cell line and reagents
MDA-MB-468 cells were obtained from the American
Type Tissue Culture Collection and cultured in Dulbecco's
modified Eagle's medium/F12 medium supplemented
with 10% fetal bovine serum at 37°C and humidified in
5% CO2. Rapamycin was purchased from LC Laborato-
ries. All other chemicals were purchased from Sigma
Chemical Company and Fisher Scientific.
Cell proliferation assay and dose-effect analysis
To test the effect of rapamycin, 5 × 103 MDA-MB-468 cells
per 100 μL per well were plated in 96-well flat-bottomed
plates. After overnight incubation, cells in triplicate wells
were treated with rapamycin at various concentrations for
5 days. Cell proliferation was then analyzed by comparing
the protein content of rapamycin-treated cells with that of
vehicle (dimethyl sulfoxide [DMSO])-treated cells using a
sulforhodamine B (SRB) assay. The assay results were
assessed using a 96-well plate reader by measuring the
absorbance at a wavelength of 570 nm. The IC50  of
rapamycin was determined based on dose-response
curves using the SRB assay with the CalcuSyn software
program (Biosoft). Experiments were repeated three
times, and the mean IC50 values are reported.
Colony formation assay
MDA-MB-468 cells were plated at a density of 2 × 103 cells
per 60-mm plate in triplicate. After overnight incubation,
cells were treated with DMSO or 100 nM rapamycin. Two
weeks later, plates were fixed, stained with crystal violet,
and scanned, and the cell colonies in the plates were
counted using the ImageJ software program (National
Institutes of Health).
Animal studies
All animal studies were conducted according to the guide-
lines of the American Association of Laboratory Animal
Care under an approved protocol. Eight-week-old female
athymic nude (nu/nu) mice (Harlan Sprague Dawley Inc.)
were inoculated with 1.5 × 107 MDA-MB-468 cells in the
mammary fat pad. Thirty days after inoculation, the
resulting breast tumor volumes had reached 75-150 mm3,
and the mice were placed in four experimental groups.
The mice in the first and second groups (five per group)
received a single injection of DMSO or rapamycin (15 mg/
kg) intraperitoneally. The mice in the third and fourth
groups (five per group) received weekly injections of
DMSO or rapamycin for 3 weeks. The tumors were meas-
ured every other day using calipers and the formula 1/2 ×
a2 × b, in which a is the short axis and b is the long axis.
Twenty-four hours after the last injection, the mice were
killed using cervical dislocation. Samples of the tumors
were collected in RNAlater (Ambion) for RNA extraction.
Total RNA extraction, amplification, labeling, and 
hybridization
Total RNA was extracted from MDA-MB-468 cells using
TRIzol reagent (Invitrogen) according to the manufac-
turer's recommendations. Total RNA was also extracted
from the breast tumor xenografts described above using
an RNeasy kit (Qiagen) following the manufacturer's rec-
ommendations. RNA purity and integrity were controlled
using a 2100 Bioanalyzer (Agilent Technologies). Total
RNA was extracted from three separate MDA-MB-468 cell
culture plates or breast tumor samples for each treatment
condition, as described above, generating 18 RNA-extrac-
tion experiments (6 with MDA-MB-468 cell line and 12
with xenograft samples).
Microarray hybridization analysis was performed accord-
ing to the protocol described in the Affymetrix Expression
Analysis Technical Manual. Briefly, 5 μg of total RNA
extracted from cell culture or xenograft was reverse-tran-
scribed and amplified. The RNA was labeled using the
BioArray high-yield RNA transcript labeling kit (Enzo Bio-
chem Inc.) following the manufacturer's recommenda-Molecular Cancer 2009, 8:75 http://www.molecular-cancer.com/content/8/1/75
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tions. Biotin-labeled cRNA was purified, quantified, and
fragmented. Hybridization and scanning were performed
at The University of Texas M. D. Anderson Cancer Center
Microarray Core Facility. Fifteen micrograms of labeled
cRNA was then hybridized to Affymetrix Human Genome
U133 (HG-U133) Plus 2.0 chips (Affymetrix, Inc.). The
chips were washed and stained according to the Affyme-
trix Expression Analysis Technical Manual.
Microarray gene expression analysis
All data preprocessing and statistical analyses were per-
formed in R software. As part of standard quality control
analysis, the .CEL files were quantified using the MAS5
algorithm. The probe intensities were processed using a
position-dependent nearest neighbor (PDNN) model to
estimate gene expression values [49]. Array images, mark-
ers bar plot, box plot, and sample cluster figures were gen-
erated to confirm the data quality. Paired and unpaired
Student  t-tests were used to determine the effect of
rapamycin in our cell culture study and animal study,
respectively. T statistics, fold change, and P values were
computed for all probe sets separately. A beta-uniform
mixture analysis was performed to assess statistical signif-
icance and control the false-discovery rate (FDR) [50].
Independent data sets
Publicly available primary breast cancer data sets
described by Miller et al. [27], van 't Veer et al. [29], and
Wang et al. [28] were used in this study.
Statistical analysis
For in vitro and in vivo studies, treatment groups of mice
were compared using the Student t-test. Rapamycin meta-
gene index is calculated as the mean of the log-expression
values of 29 genes (represented by 31 probe sets). A Cox
proportional hazards model was used to examine whether
the (RMI) is an independent prognostic factor for breast
cancer. To show the association of RMI with survival, Cox
regression analysis of the samples that have "high" (>75th
percentile) and "low" (<25th percentile) RMI values was
performed. Traditional proportional hazards analysis was
established and quantified the prognostic relevance of
clinical and biological factors, including lymph node sta-
tus, tumor size, age, grade, and estrogen receptor status, to
the RMI using traditional proportional hazards analysis.
The Wilcoxon rank test was used to determine how clini-
cal factors were correlated with the high and low RMI val-
ues. All P values were two-sided, and P values less than
0.05 were considered significant.
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